STOCK TITAN

Intercept to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Intercept Pharmaceuticals (Nasdaq:ICPT) announced that its executives will participate in virtual fireside chats at two investor conferences. Jerry Durso, M. Michelle Berrey, Linda Richardson, and Andrew Saik will present at the 2021 Jefferies London Healthcare Conference on November 18, 2021, and at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021. The presentations will be accessible on Intercept’s investor page, with an audio archive available for two weeks post-event.

Positive
  • None.
Negative
  • None.

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept; M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept; Linda Richardson, Chief Commercial Officer of Intercept; and Andrew Saik, Chief Financial Officer of Intercept, will participate virtually in fireside chats at the following upcoming investor conferences:

  • The 2021 Jefferies London Healthcare Conference, for which the pre-recorded chat will be made available on November 18, 2021;
  • The Piper Sandler 33rd Annual Virtual Healthcare Conference, for which the pre-recorded chat will be made available on November 22, 2021.

The presentations can be accessed on the investor page of Intercept’s website at http://ir.interceptpharma.com, and an audio archive of the pre-recorded chats will also be available on Intercept’s website for approximately two weeks from the time they are made available.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Investor inquiries:  investors@interceptpharma.com

Media inquiries: media@interceptpharma.com


FAQ

When will Intercept Pharmaceuticals executives speak at upcoming investor conferences?

Intercept Pharmaceuticals executives will participate in fireside chats at the Jefferies London Healthcare Conference on November 18, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021.

Where can I access the presentations of Intercept Pharmaceuticals at the conferences?

The presentations can be accessed on the investor page of Intercept Pharmaceuticals' website.

How long will the audio archive of Intercept Pharmaceuticals' presentations be available?

The audio archive will be available for approximately two weeks from the time the presentations are made available.

What is the focus area of Intercept Pharmaceuticals?

Intercept Pharmaceuticals focuses on developing novel therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Intercept Pharmaceuticals, Inc.

NASDAQ:ICPT

ICPT Rankings

ICPT Latest News

ICPT Stock Data

794.69M
34.49M
3.13%
81.3%
24.24%
Biotechnology
Healthcare
Link
United States
Morristown